MA47849A - Anticorps anti-gitr et leurs procédés d'utilisation - Google Patents

Anticorps anti-gitr et leurs procédés d'utilisation

Info

Publication number
MA47849A
MA47849A MA047849A MA47849A MA47849A MA 47849 A MA47849 A MA 47849A MA 047849 A MA047849 A MA 047849A MA 47849 A MA47849 A MA 47849A MA 47849 A MA47849 A MA 47849A
Authority
MA
Morocco
Prior art keywords
methods
gitr antibodies
gitr
antibodies
Prior art date
Application number
MA047849A
Other languages
English (en)
Inventor
Ana M Gonzalez
Olivier Léger
Taha Merghoub
Gerd Ritter
David Schaer
Volker Seibert
Takemasa Tsuji
Dennis J Underwood
Dijk Marc Van
Nicholas S Wilson
Jedd David Wolchok
Roberta Zappasodi
Original Assignee
Agenus Inc
Ludwig Inst For Cancer Res Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc, Ludwig Inst For Cancer Res Ltd, Memorial Sloan Kettering Cancer Center filed Critical Agenus Inc
Publication of MA47849A publication Critical patent/MA47849A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
MA047849A 2014-05-28 2015-05-28 Anticorps anti-gitr et leurs procédés d'utilisation MA47849A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004071P 2014-05-28 2014-05-28
US201562161250P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
MA47849A true MA47849A (fr) 2020-01-29

Family

ID=53433276

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40041A MA40041B1 (fr) 2014-05-28 2015-05-28 Anticorps anti-gitr et leurs procédés d'utilisation
MA047849A MA47849A (fr) 2014-05-28 2015-05-28 Anticorps anti-gitr et leurs procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40041A MA40041B1 (fr) 2014-05-28 2015-05-28 Anticorps anti-gitr et leurs procédés d'utilisation

Country Status (26)

Country Link
US (9) US10155818B2 (fr)
EP (2) EP3498295A1 (fr)
JP (3) JP6847666B2 (fr)
KR (2) KR20220116578A (fr)
CN (2) CN108064242B (fr)
AU (3) AU2015266958A1 (fr)
CA (1) CA2949998A1 (fr)
CY (1) CY1124787T1 (fr)
DK (1) DK3148579T3 (fr)
EA (1) EA201692458A1 (fr)
ES (1) ES2860751T3 (fr)
HR (1) HRP20210364T1 (fr)
HU (1) HUE053857T2 (fr)
IL (3) IL293212B2 (fr)
LT (1) LT3148579T (fr)
MA (2) MA40041B1 (fr)
MX (2) MX2016015614A (fr)
NZ (1) NZ726513A (fr)
PH (1) PH12016502345A1 (fr)
PL (1) PL3148579T3 (fr)
PT (1) PT3148579T (fr)
RS (1) RS61678B1 (fr)
SG (2) SG10201912986PA (fr)
SI (1) SI3148579T1 (fr)
TW (2) TWI709573B (fr)
WO (1) WO2015184099A1 (fr)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140212398A1 (en) 2011-09-08 2014-07-31 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
ES2755395T3 (es) 2014-06-06 2020-04-22 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
EP3215141A4 (fr) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Agents immunorégulateurs
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
PT3218005T (pt) 2014-11-12 2023-04-11 Seagen Inc Compostos que interagem com glicano e métodos de uso
CN113577264A (zh) 2015-04-17 2021-11-02 百时美施贵宝公司 包含抗pd-1抗体和另外的抗体的组合的组合物
CA2988115A1 (fr) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anticorps anti-gitr pour le diagnostic du cancer
US10933124B2 (en) 2015-07-16 2021-03-02 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
BR112018001161A2 (pt) 2015-07-23 2018-09-18 Inhibrx Lp proteínas de fusão de ligação a gitr multiespecíficas e multivalentes
AU2016341403B2 (en) 2015-10-22 2023-08-03 Ablynx Nv GITR agonists
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
SG11201803817PA (en) 2015-11-19 2018-06-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
AU2016364895A1 (en) * 2015-12-02 2018-06-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CN108883173B (zh) * 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
WO2017096276A1 (fr) * 2015-12-02 2017-06-08 Agenus Inc. Anticorps anti-gitr et procédés d'utilisation associés
JP6976265B2 (ja) 2016-03-08 2021-12-08 ヤンセン バイオテツク，インコーポレーテツド Ｇｉｔｒ抗体、方法、及び使用
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
JP2019528082A (ja) * 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
SG11201810525XA (en) 2016-06-10 2018-12-28 Regeneron Pharma Anti-gitr antibodies and uses thereof
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
JP2019519536A (ja) * 2016-07-01 2019-07-11 ファイブ プライム セラピューティクス， インコーポレイテッド Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JP2019528683A (ja) * 2016-07-20 2019-10-17 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｇｉｔｒ結合分子及びその使用
CN116082506A (zh) 2016-07-22 2023-05-09 丹娜法伯癌症研究所公司 糖皮质激素诱导肿瘤坏死因子受体(gitr)抗体及其使用方法
MA46770A (fr) * 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US20200247902A1 (en) * 2016-11-17 2020-08-06 Seattle Genetics, Inc. Compositions and methods for treating cancer
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
JP7169296B2 (ja) 2017-01-27 2022-11-10 ウルトラヒューマン ワン リミティド 結合剤
MX2019009619A (es) 2017-02-10 2019-12-18 Eutilex Co Ltd Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.
US11292842B2 (en) 2017-02-21 2022-04-05 Regeneron Pharmaceuticals, Inc. Anti-PD-1 antibodies for treatment of lung cancer
AU2018226824A1 (en) 2017-03-03 2019-09-19 Seagen Inc. Glycan-interacting compounds and methods of use
AU2018243754A1 (en) 2017-03-31 2019-10-17 Bristol-Myers Squibb Company Methods of treating tumor
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
CN109136275B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化gitr基因改造动物模型的制备方法及应用
KR20200019865A (ko) 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
EA202090104A1 (ru) 2017-06-22 2020-04-09 Новартис Аг Молекулы антител к cd73 и пути их применения
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
JP2020532279A (ja) * 2017-06-30 2020-11-12 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 抗ｇｉｔｒ抗体、その抗原結合性断片、およびその医薬用途
EP3645008A4 (fr) * 2017-06-30 2020-12-09 Bristol-Myers Squibb Company Composés quinolinycyclohexylpropanamide substitués et procédés améliorés pour leur préparation
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
WO2019046338A1 (fr) * 2017-08-28 2019-03-07 Angiex, Inc. Anticorps anti-tm4sf1 et leurs procédés d'utilisation
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
WO2019081983A1 (fr) 2017-10-25 2019-05-02 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation
WO2019099838A1 (fr) 2017-11-16 2019-05-23 Novartis Ag Polythérapies
CN111886255A (zh) 2018-01-12 2020-11-03 百时美施贵宝公司 抗tim3抗体及其用途
CA3089653A1 (fr) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anticorps anti-claudine 18.2 et leurs utilisations
CN111971304A (zh) 2018-03-21 2020-11-20 戊瑞治疗有限公司 在酸性pH结合至VISTA的抗体
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
EP3774840A1 (fr) 2018-03-27 2021-02-17 Bristol-Myers Squibb Company Surveillance en temps réel de la concentration de protéines à l'aide d'un signal ultraviolet
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
MX2021000009A (es) 2018-07-09 2021-03-09 Five Prime Therapeutics Inc Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
FI3820573T3 (fi) 2018-07-10 2023-11-01 Novartis Ag 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
KR20210041036A (ko) * 2018-08-08 2021-04-14 세다르스-신나이 메디칼 센터 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법
KR20210086623A (ko) 2018-09-25 2021-07-08 하푼 테라퓨틱스, 인크. Ddl3 결합 단백질 및 사용 방법
WO2020089811A1 (fr) 2018-10-31 2020-05-07 Novartis Ag Conjugué médicament-anticorps anti-dc-sign
CA3123511A1 (fr) 2018-12-20 2020-06-25 Novartis Ag Schema posologique et combinaison pharmaceutique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
EP3897613A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1bêta
EP3898674A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps se liant à il-1bêta
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
CA3123519A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Derives de 3-(1-oxoisoindoline-2-yl)piperidine-2,6-dione substitues et leurs utilisations
WO2020165833A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
EP3973274A1 (fr) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Méthodes de surveillance de milieu
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
JP2022548292A (ja) 2019-09-19 2022-11-17 ブリストル－マイヤーズ スクイブ カンパニー 酸性ｐＨでＶＩＳＴＡと結合する抗体
EP4048285A1 (fr) 2019-10-21 2022-08-31 Novartis AG Inhibiteurs de tim-3 et leurs utilisations
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
WO2021127217A1 (fr) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
IL293752A (en) 2020-01-17 2022-08-01 Novartis Ag A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
IL296043A (en) 2020-03-06 2022-10-01 Regeneron Pharma Anti-gitro antibodies and their uses
JPWO2021225159A1 (fr) * 2020-05-08 2021-11-11
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022029573A1 (fr) 2020-08-03 2022-02-10 Novartis Ag Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations
EP4204021A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
WO2022043558A1 (fr) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Méthode de traitement de cancers exprimant le psma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4225770A1 (fr) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Procédés pour concentrer des protéines
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
EP4267172A1 (fr) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Administration sous-cutanée d'anticorps pd1/pd-l1
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
AU2022209701A1 (en) * 2021-01-21 2023-08-31 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
TW202246334A (zh) 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117813327A (zh) * 2021-05-10 2024-04-02 美帝马布生物公司 抗gitr抗体及其用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3224374A1 (fr) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiees pour favoriser la thanotransmission de phenylethanolamines et leurs utilisations
WO2023173011A1 (fr) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Expression transitoire de protéines thérapeutiques
WO2023178192A1 (fr) 2022-03-15 2023-09-21 Compugen Ltd. Anticorps antagonistes de l'il-18bp et leur utilisation en monothérapie et polythérapie dans le traitement du cancer
WO2023175614A1 (fr) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anticorps anti-protéine liée au tnfr induite par glucocorticoïdes (gitr) et leurs utilisations
WO2023178329A1 (fr) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Procédés d'isolement de polypeptides
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
WO2024097328A1 (fr) * 2022-11-03 2024-05-10 Incyte Corporation Polythérapies comprenant un anticorps anti-gitr pour le traitement de cancers

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
WO1992022324A1 (fr) 1991-06-14 1992-12-23 Xoma Corporation Fragments d'anticorps produits par des microbes et leurs conjugues
CA2103059C (fr) 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP1291360A1 (fr) 1991-12-13 2003-03-12 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
EP0640094A1 (fr) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994013804A1 (fr) 1992-12-04 1994-06-23 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
WO1995001997A1 (fr) 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
CN1110557C (zh) 1994-05-06 2003-06-04 古斯达威罗斯研究所 Lag－3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69624824T2 (de) 1995-07-21 2003-09-11 Applied Research Systems Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6027947A (en) 1996-08-20 2000-02-22 Ramtron International Corporation Partially or completely encapsulated top electrode of a ferroelectric capacitor
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CN1233954A (zh) 1996-10-01 1999-11-03 西马实验室股份有限公司 掩盖味道的微胶囊组合物及其制备方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
EP0942968B1 (fr) 1996-12-03 2008-02-27 Amgen Fremont Inc. Anticorps d'origine uniquement humaine qui se lie au récepteur de l'EGF
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
PL193780B1 (pl) 1997-04-14 2007-03-30 Micromet Ag Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE69840962D1 (de) 1997-08-29 2009-08-20 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
ATE387192T1 (de) 1997-10-28 2008-03-15 Bando Chemical Ind Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO1999040196A1 (fr) 1998-02-09 1999-08-12 Genentech, Inc. Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002512776A (ja) 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
ES2257068T3 (es) 1998-08-10 2006-07-16 Antigenics Inc. Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
EP1792991A1 (fr) 1999-08-24 2007-06-06 Medarex, Inc. Anticorps humains contre CTLA-4 et leur utilisation
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP2357187A1 (fr) 2000-12-12 2011-08-17 MedImmune, LLC Molécules à demi-vies longues, compositions et utilisations de celles-ci
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2003006058A1 (fr) 2001-07-12 2003-01-23 Wyeth Marqueurs differentiels cd25+ et leurs utilisations
CA2466279A1 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
EP1467759A4 (fr) 2002-01-30 2006-05-31 Brigham & Womens Hospital Compositions et methodes associees a tim-3, molecule de surface cellulaire specifique a th1
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
EP1503794B9 (fr) 2002-04-12 2012-09-19 Medarex, Inc. Methodes de traitement dans lesquelles sont utilises des anticorps du ctla-4
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2508660C (fr) 2002-12-23 2013-08-20 Wyeth Anticorps anti pd-1 et utilisations
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
EP1897548B2 (fr) 2003-02-28 2024-05-22 The Johns Hopkins University Régulation des lymphocytes T
WO2004107618A2 (fr) 2003-05-23 2004-12-09 Wyeth Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
EP1660126A1 (fr) 2003-07-11 2006-05-31 Schering Corporation Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
EP1660534A2 (fr) 2003-08-22 2006-05-31 MedImmune, Inc. Humanisation d'anticorps
EP2289547B1 (fr) 2003-09-12 2015-12-16 Agenus Inc. Vaccin pour le traitement et la prévention de l'infection par le virus herpès simplex
EP2270511A3 (fr) 2003-10-24 2011-08-24 Immunaid Pty Ltd Procédé de thérapie
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
ES2657443T3 (es) * 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
WO2007081878A2 (fr) 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Voies d'indoléamine 2,3-dioxygénase dans la production de lymphocytes t régulateurs
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
US20070243184A1 (en) 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
US20090285834A1 (en) 2005-11-24 2009-11-19 Dainippon Sumitomo Pharma Co., Ltd. Novel memory ctl induction potentiator
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP1981969A4 (fr) 2006-01-19 2009-06-03 Genzyme Corp Anticorps anti-gitr destines au traitement du cancer
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008073160A2 (fr) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Procédés de conversion ou d'induction d'une immunité protectrice
EP1894941A1 (fr) 2006-09-01 2008-03-05 Institut Pasteur Traitment du carcinome du col de l'utérus avec une adenylate cyclase portant des antigenes HPV
EP2081961A2 (fr) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Utilisations thérapeutiques des modulateurs tim-3
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
JP2008278814A (ja) * 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
EP3124046B1 (fr) 2007-07-12 2019-12-25 GITR, Inc. Thérapies combinées utilisant des molécules de liaison gitr
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2009045443A2 (fr) 2007-10-02 2009-04-09 The University Of Rochester Méthodes et compositions associées aux réponses synergiques aux mutations oncogènes
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2240204A1 (fr) 2008-02-04 2010-10-20 Medarex, Inc. Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
NO2824100T3 (fr) 2008-07-08 2018-07-21
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20110435A1 (es) 2008-08-25 2011-07-20 Amplimmune Inc Composiciones antagonistas del pd-1
US9301785B2 (en) 2008-10-21 2016-04-05 K2M, Inc. Spinal buttress plate
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
EP2426148B1 (fr) 2009-04-27 2015-08-05 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-il-3ra destiné à être utilisé dans le traitement d'hématomes
EP2436397B1 (fr) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant un antagoniste d'un ligand de la famille de l'egf en tant que composant
EP2975051B1 (fr) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
CA2769822C (fr) 2009-08-13 2019-02-19 The Johns Hopkins University Methodes de modulation de la fonction immunitaire
EP2473531A4 (fr) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anticorps anti-gitr
CN102753195A (zh) 2009-12-07 2012-10-24 小利兰·斯坦福大学托管委员会 用于增强抗肿瘤抗体疗法的方法
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
WO2012064760A2 (fr) 2010-11-08 2012-05-18 Biovest International, Inc. Matériels et méthodes pour l'orientation d'une réponse immunitaire vers un épitope
US20130323283A1 (en) 2010-12-01 2013-12-05 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
MX353931B (es) 2011-07-11 2018-02-02 Glenmark Pharmaceuticals Sa Anticuerpos que se unen a ox40 y sus usos.
US8920075B2 (en) 2011-09-01 2014-12-30 Halo Maritime Defense Systems, Inc. Marine barrier and gate
WO2013039954A1 (fr) * 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013049307A2 (fr) 2011-09-30 2013-04-04 University Of Miami Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère
WO2013103800A1 (fr) 2012-01-06 2013-07-11 Bioalliance C.V. Anticorps de récepteur d'anti-transferrine et leurs procédés
CA2865153C (fr) 2012-02-23 2022-11-22 Sloan-Kettering Institute For Cancer Research Prediction de la sensibilite a un traitement par des produits therapeutiques d'immunomodulation et procede de surveillance des effets ascopaux au cours d'un tel traitement
WO2013142255A2 (fr) 2012-03-22 2013-09-26 University Of Miami Agents de liaison multi-spécifiques
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014022592A1 (fr) 2012-08-02 2014-02-06 Jn Biosciences Llc Anticorps ou protéines de fusion multimérisés par l'intermédiaire de la mutation d'une cystéine et une pièce de queue μ
PT2925350T (pt) 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
WO2014121099A1 (fr) 2013-01-31 2014-08-07 Thomas Jefferson University Protéine de fusion agoniste des cd40 ox40 et ses utilisations
JP6449229B2 (ja) 2013-03-15 2019-01-09 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｆｃ変異体
CA2906927C (fr) 2013-03-15 2021-07-13 Xencor, Inc. Modulation de cellules t avec des anticorps bispecifiques et des fusions de fc
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
EP3021869B1 (fr) 2013-07-16 2020-07-15 F. Hoffmann-La Roche AG Procédés de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et inhibiteurs de tigit
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015095811A2 (fr) 2013-12-20 2015-06-25 The Board Institute Inc. Polythérapie comprenant un vaccin à base de néoantigènes
US11059898B2 (en) 2014-03-24 2021-07-13 Cancer Research Technology Limited Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
ES2755395T3 (es) 2014-06-06 2020-04-22 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA40475A (fr) 2014-08-19 2017-06-28 Fayadat Dilman Laurence Anticorps anti-tigit
US10463732B2 (en) 2014-10-03 2019-11-05 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN108064252A (zh) 2014-12-19 2018-05-22 达纳－法伯癌症研究所公司 嵌合抗原受体及其使用方法
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2016154544A1 (fr) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions et procédés permettant d'administrer des agents de type biomacromolécule
CN113577264A (zh) 2015-04-17 2021-11-02 百时美施贵宝公司 包含抗pd-1抗体和另外的抗体的组合的组合物
WO2017096276A1 (fr) 2015-12-02 2017-06-08 Agenus Inc. Anticorps anti-gitr et procédés d'utilisation associés
AU2016364895A1 (en) 2015-12-02 2018-06-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation

Also Published As

Publication number Publication date
MA40041A (fr) 2017-04-05
US20190010239A1 (en) 2019-01-10
CA2949998A1 (fr) 2015-12-03
NZ726513A (en) 2023-07-28
AU2021200582B2 (en) 2022-05-12
JP6847666B2 (ja) 2021-03-24
US20200339698A1 (en) 2020-10-29
US20190309082A1 (en) 2019-10-10
US20180355051A1 (en) 2018-12-13
KR102433464B1 (ko) 2022-08-17
MX2020013062A (es) 2021-03-02
DK3148579T3 (da) 2021-03-08
PT3148579T (pt) 2021-03-11
CY1124787T1 (el) 2022-11-25
SG11201609721WA (en) 2016-12-29
TWI709573B (zh) 2020-11-11
WO2015184099A1 (fr) 2015-12-03
US10800849B2 (en) 2020-10-13
US20190062446A1 (en) 2019-02-28
JP2023021446A (ja) 2023-02-10
EP3498295A1 (fr) 2019-06-19
US11897962B2 (en) 2024-02-13
PH12016502345A1 (en) 2017-02-13
RS61678B1 (sr) 2021-05-31
IL304178A (en) 2023-09-01
EP3148579A1 (fr) 2017-04-05
US20180244793A1 (en) 2018-08-30
US10829559B2 (en) 2020-11-10
MX2016015614A (es) 2017-08-21
EP3148579B1 (fr) 2020-12-16
JP2017526615A (ja) 2017-09-14
JP2020048584A (ja) 2020-04-02
IL293212B1 (en) 2023-08-01
US11401335B2 (en) 2022-08-02
TW201607958A (zh) 2016-03-01
CN115925946A (zh) 2023-04-07
HRP20210364T1 (hr) 2021-04-30
AU2021200582A1 (en) 2021-03-04
AU2015266958A1 (en) 2016-12-08
IL293212A (en) 2022-07-01
SI3148579T1 (sl) 2021-07-30
HUE053857T2 (hu) 2021-07-28
ES2860751T3 (es) 2021-10-05
AU2022215304A1 (en) 2022-09-08
CN108064242B (zh) 2022-10-21
KR20170020819A (ko) 2017-02-24
US10155818B2 (en) 2018-12-18
IL249092B (en) 2022-07-01
EA201692458A1 (ru) 2017-06-30
IL249092A0 (en) 2017-01-31
CN108064242A (zh) 2018-05-22
US10577426B2 (en) 2020-03-03
TW202132337A (zh) 2021-09-01
US10280226B2 (en) 2019-05-07
SG10201912986PA (en) 2020-02-27
MA40041B1 (fr) 2021-03-31
US20210070872A1 (en) 2021-03-11
LT3148579T (lt) 2021-05-25
US20150368349A1 (en) 2015-12-24
IL293212B2 (en) 2023-12-01
PL3148579T3 (pl) 2021-07-19
US20230039577A1 (en) 2023-02-09
KR20220116578A (ko) 2022-08-23

Similar Documents

Publication Publication Date Title
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
FR22C1048I2 (fr) Anticorps anti-cd3 et méthodes d'utilisation
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci